Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial

IMPORTANCE: Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) therapy. Few studies of anemia treatment in an incident dialysis (ID) population have been reported. OBJECTIVE: To evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ajay K., Cizman, Borut, Carroll, Kevin, McMurray, John J. V., Perkovic, Vlado, Jha, Vivekanand, Johansen, Kirsten L., Lopes, Renato D., Macdougall, Iain C., Obrador, Gregorio T., Waikar, Sushrut S., Wanner, Christoph, Wheeler, David C., Wiecek, Andrzej, Stankus, Nicole, Strutz, Frank, Blackorby, Allison, Cobitz, Alexander R., Meadowcroft, Amy M., Paul, Gitanjali, Ranganathan, Prerna, Sedani, Sangeeta, Solomon, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981070/
https://www.ncbi.nlm.nih.gov/pubmed/35377393
http://dx.doi.org/10.1001/jamainternmed.2022.0605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981070/
https://www.ncbi.nlm.nih.gov/pubmed/35377393
http://dx.doi.org/10.1001/jamainternmed.2022.0605

Ejemplares similares